Research graph
References from Myositis autoantibodies: from new specificities to new paradigms. Local targets link to admitted publications; unresolved targets remain external evidence.
Polymyositis and dermatomyositis (first of two parts)
10.1056/nejm197502132920706 · 1975 · External reference
Polymyositis and dermatomyositis (second of two parts)
10.1056/nejm197502202920807 · 1975 · External reference
Description of a serological reaction characteristic of polymyositis
10.1016/0090-1229(76)90145-8 · 1976 · External reference
The association between Mi-2 antibodies and dermatomyositis
10.1002/art.1780280711 · 1985 · External reference
Purification and characterization of a nuclear nonhistone basic protein (Mi-1) which reacts with antiimmunoglobulin sera and the sera of patients with dermatomyositis
10.1016/0161-5890(80)90109-1 · 1980 · External reference
Clinical characteristics of anti-synthetase syndrome: analysis from the Classification Criteria for Anti-Synthetase Syndrome Project
10.1002/art.43038 · 2025 · External reference
Autoantigenic properties of the aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies
10.1016/j.jaut.2022.102951 · 2023 · External reference
Newer autoantibodies and laboratory assessments in myositis
10.1007/s11926-024-01171-8 · 2024 · External reference
Evaluation of multitRNA synthetase complex by multiple reaction monitoring mass spectrometry coupled with size exclusion chromatography
10.1371/journal.pone.0142253 · 2015 · External reference
Two novel antiaminoacyl tRNA synthetase antibodies: autoantibodies against cysteinyl-tRNA synthetase and valyl-tRNA synthetase
10.1016/j.autrev.2022.103204 · 2022 · External reference
Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies
10.1136/ard-2022-222686 · 2023 · External reference
Reaction of anti-OJ autoantibodies with components of the multienzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase
10.1172/jci116493 · 1993 · External reference
Analytical performance of commercial myositis-specific autoantibody tests evaluated against immunoprecipitation assays as a reference standard: A systematic review and meta-analysis
10.1016/j.semarthrit.2025.152858 · 2025 · External reference
The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity
10.1093/rheumatology/keaa021 · 2020 · External reference
Phage ImmunoPrecipitation sequencing (PhIP-Seq) in autoimmunity research: From high-resolution epitope mapping to multiomics integration
10.1016/j.autrev.2026.104094 · 2026 · External reference
Laboratory testing for antisynthetase antibodies: a novel algorithm to improve diagnostic accuracy
10.1016/j.cca.2026.121076 · 2026 · External reference
Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies
10.1172/jci81031 · 2015 · External reference
Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis
10.1093/rheumatology/kez406 · 2020 · External reference
Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis
10.1093/rheumatology/keab846 · 2022 · External reference
Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics
10.1093/rheumatology/kex468 · 2018 · External reference
Association of anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis
10.1093/rheumatology/kead203 · 2023 · External reference
Autoantibodies against a subunit of mitochondrial respiratory chain complex I in inclusion body myositis
10.1016/j.jaut.2024.103332 · 2024 · External reference
224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016
10.1016/j.nmd.2017.09.016 · 2018 · External reference
Idiopathic inflammatory myopathies related lung disease in adults
10.1016/s2213-2600(24)00267-4 · 2025 · External reference
Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies
10.1016/j.ebiom.2023.104804 · 2023 · External reference
Increased cytokine levels in seronegative myositis: potential Th17 immune response implications
10.3390/ijms252011061 · 2024 · External reference
Clinical features and immunogenetic risk factors associated with additional autoantibodies in anti-transcriptional intermediary factor 1gamma juvenile-onset dermatomyositis
10.1002/art.42768 · 2024 · External reference
CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes
10.1016/j.molcel.2008.08.001 · 2008 · External reference
CARP-1/CCAR1: a biphasic regulator of cancer cell growth and apoptosis
10.18632/oncotarget.3376 · 2015 · External reference
Sp4, a member of the Sp1-family of zinc finger transcription factors, is required for normal murine growth, viability, and male fertility
10.1006/dbio.1996.0134 · 1996 · External reference
Association of anti-CCAR1 autoantibodies with decreased cancer risk relative to the general population in patients with anti-transcriptional intermediary factor 1gamma-positive dermatomyositis
10.1002/art.42474 · 2023 · External reference
Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence
10.1172/jci150201 · 2022 · External reference
Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1gamma autoantibodies
10.1136/ard-2022-222441 · 2023 · External reference
Autoantibodies recognizing specificity protein 4 co-occur with anti-transcription intermediary factor 1 and are associated with distinct clinical features and immunogenetic risk factors in juvenile myositis
10.1002/art.42512 · 2023 · External reference
The relationship between anti-cell division cycle and apoptosis regulator 1 autoantibodies, anti-Sp4 autoantibodies, and cancer in anti-transcription intermediary factor 1gamma-positive dermatomyositis
10.1002/acr2.11750 · 2024 · External reference
Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases
10.1212/wnl.0000000000009727 · 2020 · External reference
Coexistence of antimelanoma differentiation-associated protein 5 and anti-Ro52 antibodies in patients with idiopathic inflammatory myopathy: a retrospective cohort study
10.1007/s10067-025-07562-1 · 2025 · External reference
Identification of three different phenotypes in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease
10.1002/art.42308 · 2023 · External reference
Comparative B cell epitope profiling in Japanese and North American cohorts of MDA5+ dermatomyositis patients reveals a direct association between immune repertoire and pulmonary mortality
10.1093/rheumatology/keae466 · 2025 · External reference
MDA5 dermatomyositis: unveiling a potentially life-threatening disease
10.3949/ccjm.92a.25018 · 2025 · External reference
Distinct anti-MDA5 antibody trajectories associated with long-term outcomes in 6-month survivors of anti-MDA5 dermatomyositis with interstitial lung disease
10.1186/s12931-026-03572-y · 2026 · External reference
Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease
10.1093/rheumatology/keac229 · 2022 · External reference
Anti-MDA5 antibody IgG1 subtype is associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis
10.1186/s13023-025-03921-y · 2025 · External reference
Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy
10.1002/art.22865 · 2007 · External reference
Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and antisynthetase syndrome
10.1186/s13075-022-02745-6 · 2022 · External reference
Anti-Jo-1 autoantibodies: biomarkers of severity and evolution of the disease in antisynthetase syndrome
10.1186/s13075-023-03116-5 · 2023 · External reference
Antibody levels correlate with creatine kinase levels and strength in anti3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy
10.1002/art.34673 · 2012 · External reference
Correlation of antisignal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy
10.1002/art.30344 · 2011 · External reference
Dermatomyositis: muscle pathology according to antibody subtypes
10.1212/wnl.0000000000013176 · 2022 · External reference
Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies
10.1111/ane.13331 · 2021 · External reference
Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China
10.1007/s10067-022-06291-z · 2022 · External reference
Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity
10.1084/jem.190.6.815 · 1999 · External reference
Epitope mapping of the cloned human autoantigen, histidyl-tRNA synthetase. Analysis of the myositis-associated anti-Jo-1 autoimmune response
10.4049/jimmunol.143.7.2267 · 1989 · External reference
Autoantibodies against the melanoma differentiation-associated protein 5 in patients with dermatomyositis target the helicase domains
10.1093/rheumatology/kead400 · 2024 · External reference
The central helicase domain holds the major conformational epitopes of melanoma differentiation-associated gene 5 autoantibodies
10.1093/rheumatology/kead397 · 2024 · External reference
PhIP-Seq: unveiling the complexity of antibody repertoires in health and disease
10.3389/fimmu.2026.1735735 · 2026 · External reference
Anti-MDA5 monoclonal antibodies from patients with dermatomyositis - B cell characteristics and differential targeting of the helicase domains
10.1016/j.jaut.2026.103536 · 2026 · External reference
Epitope spreading in immune-mediated diseases: implications for immunotherapy
10.1038/nri724 · 2002 · External reference
B cell epitope spreading: mechanisms and contribution to autoimmune diseases
10.1016/j.imlet.2014.11.001 · 2015 · External reference
Myositis-specific autoantibodies recognising Mi2 also target the AIRE protein at a shared PHD zinc finger
10.1016/j.ard.2025.08.023 · 2026 · External reference
Anti-Mi2 autoantibodies target PHD fingers of SP140L and TIF1gamma, while anti-TIF1gamma autoantibodies primarily bind TIF1gamma outside the PHD region
10.1093/rheumatology/keaf426 · 2025 · External reference
Critical requirement for professional APCs in eliciting T cell responses to novel fragments of histidyl-tRNA synthetase (Jo-1) in Jo-1 antibody-positive polymyositis
10.4049/jimmunol.169.12.7127 · 2002 · External reference
Proinflammatory histidyl-transfer RNA synthetase-specific CD4+ T cells in the blood and lungs of patients with idiopathic inflammatory myopathies
10.1002/art.41075 · 2020 · External reference
Autoreactive T cells identified in patients with anti-Jo1+ antisynthetase syndrome recognise a new epitope on histidyl t-RNA synthetase
10.1016/j.ard.2025.09.015 · 2026 · External reference
Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups
10.1136/annrheumdis-2019-215046 · 2019 · External reference
Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes
10.1038/gene.2015.28 · 2015 · External reference
Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5
10.1016/j.cell.2012.11.048 · 2013 · External reference
VASP-mediated actin dynamics activate and recruit a filopodia myosin
2021 · External reference
RNA-containing immune complexes formed by anti-melanoma differentiation associated gene 5 autoantibody are potent inducers of IFN-alpha
10.3389/fimmu.2021.743704 · 2021 · External reference
Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis
10.4049/jimmunol.144.5.1737 · 1990 · External reference
Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera
10.1016/j.jaut.2021.102680 · 2021 · External reference
Clinical characteristics and cancer risk of anti-OJ antisynthetase syndrome: a cohort comparative study and a systematic literature review
10.1016/j.autrev.2026.104032 · 2026 · External reference
Anti-OJ autoantibodies: rare or underdetected?
10.1016/j.autrev.2019.05.002 · 2019 · External reference
Immune-mediated necrotizing myopathy: clinical features and pathogenesis
10.1038/s41584-020-00515-9 · 2020 · External reference
Immune-mediated necrotizing myopathy associated with statins
10.1002/mus.21486 · 2010 · External reference
Muscle symptoms associated with statins: a series of twenty patients
10.1111/j.1742-7843.2006.pto_193.x · 2006 · External reference
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy
10.1002/art.30156 · 2011 · External reference
Anti-HMGCR myopathy
10.3233/jnd-170282 · 2018 · External reference
In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis
10.1016/j.ard.2025.04.027 · 2025 · External reference
Advances in the classification and management of idiopathic inflammatory myopathies
10.1016/s1474-4422(25)00233-9 · 2025 · External reference
The pathogenesis of immune-mediated necrotizing myopathy: progress and therapeutic implications
10.1016/j.biopha.2025.118525 · 2025 · External reference
Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM)
10.1016/j.jneuroim.2013.08.008 · 2013 · External reference
Necrosis in anti-SRP(+) and anti-HMGCR(+)myopathies: role of autoantibodies and complement
10.1212/wnl.0000000000004923 · 2018 · External reference
Pathogenic role of antisignal recognition protein and anti3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies
10.1002/ana.24902 · 2017 · External reference
In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy
10.1136/annrheumdis-2018-213518 · 2019 · External reference
Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5
10.1084/jem.20080091 · 2008 · External reference
Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity
10.1016/j.pharmthera.2009.06.012 · 2009 · External reference
A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy
10.1007/s12016-015-8510-y · 2017 · External reference
A balancing act: MDA5 in Antiviral Immunity and Autoinflammation
10.1016/j.tim.2018.08.007 · 2019 · External reference
RIG-I-like receptors: their regulation and roles in RNA sensing
10.1038/s41577-020-0288-3 · 2020 · External reference
RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease
10.1002/art.24621 · 2009 · External reference
Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression
10.1016/j.ajpath.2015.11.010 · 2016 · External reference
Mitochondrial morphology and MAVS-IFN1 signaling pathway in muscles of anti-MDA5 dermatomyositis
10.1002/acn3.51311 · 2021 · External reference
Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis
10.1007/s10067-017-3799-y · 2018 · External reference
Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies
10.1172/jci.insight.134189 · 2020 · External reference
A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies
10.1002/art.22860 · 2007 · External reference
TLR7/8 activation in immune cells and muscle by RNA-containing immune complexes: role in inflammation and the pathogenesis of myositis
10.1002/art.42989 · 2025 · External reference
Dysregulated type I/III interferon system in circulation from patients with anti-MDA5-positive dermatomyositis
10.1038/s41598-025-10895-1 · 2025 · External reference
The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study
10.1016/j.jaad.2010.09.016 · 2011 · External reference
Enhanced skin expression of melanoma differentiation-associated gene 5 (MDA5) in dermatomyositis and related autoimmune diseases
10.1016/j.jaad.2010.08.004 · 2011 · External reference
Aberrant activation of the type I interferon system may contribute to the pathogenesis of antimelanoma differentiation-associated gene 5 dermatomyositis
10.1111/bjd.16917 · 2019 · External reference
Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies
10.3389/fimmu.2021.773352 · 2021 · External reference
A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis
10.1111/cei.13404 · 2020 · External reference
Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis
10.1016/j.rmed.2015.07.004 · 2015 · External reference
Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD
10.1093/rheumatology/kez185 · 2019 · External reference
Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients
10.3389/fimmu.2023.1151695 · 2023 · External reference
Autoimmunity against melanoma differentiation-associated gene 5 induces interstitial lung disease mimicking dermatomyositis in mice
10.1073/pnas.2313070121 · 2024 · External reference
Type 1 interferons inhibit myotube formation independently of upregulation of interferon-stimulated gene 15
10.1371/journal.pone.0065362 · 2013 · External reference
Involvement of type I interferon signaling in muscle stem cell proliferation during dermatomyositis
10.1212/wnl.0000000000200271 · 2022 · External reference
Pathological autoantibody internalisation in myositis
10.1136/ard-2024-225773 · 2024 · External reference
Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies
10.1136/ard-2023-223873 · 2023 · External reference
Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity
10.1038/304177a0 · 1983 · External reference
Detection of myositis autoantibodies by multi-analytic immunoassays in a large multicenter cohort of patients with definite idiopathic inflammatory myopathies
10.3390/diagnostics13193080 · 2023 · External reference
Analytic and clinical validity of myositis-specific antibodies by line-blot immunoassay is essential
10.1097/rhu.0000000000002043 · 2024 · External reference
Performance of myositis-specific antibodies detected on myositis line immunoassay to diagnose and sub-classify patients with suspected idiopathic inflammatory myopathy, a retrospective records-based review
10.1111/1756-185x.14174 · 2021 · External reference
Optimizing line blot assays: impact of band intensity adjustment on diagnostic performance in myositis autoantibodies testing
10.1007/s10067-026-08153-4 · 2026 · External reference
Deciphering the autoantibody response to the OJ antigenic complex
10.3390/diagnostics13010156 · 2023 · External reference
Comprehensive assessment of innovative immunoassays for the detection of myositis specific antibodies
10.1515/cclm-2026-0179 · 2026 · External reference
Deciphering the autoreactome: massively parallelized methods for autoantibody detection in humans
10.1016/j.jim.2025.113876 · 2025 · External reference
Interlaboratory variability in laboratory testing and reporting of myositis autoantibodies
10.1016/j.jaut.2026.103548 · 2026 · External reference
Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort
10.1093/rheumatology/keae167 · 2024 · External reference
Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns
10.3389/fimmu.2015.00412 · 2015 · External reference
Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective
10.1136/annrheumdis-2018-214436 · 2019 · External reference
A new diagnostic algorithm for pattern-oriented autoantibody testing according to the ICAP nomenclature: a pilot study
10.1016/j.autrev.2020.102588 · 2020 · External reference
